Medpace Holdings, Inc. (NASDAQ:MEDP) Forecasted to Post FY2024 Earnings of $11.07 Per Share

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at William Blair raised their FY2024 earnings estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, April 23rd. William Blair analyst M. Smock now forecasts that the company will post earnings of $11.07 per share for the year, up from their previous estimate of $10.55. The consensus estimate for Medpace’s current full-year earnings is $11.13 per share. William Blair also issued estimates for Medpace’s Q1 2025 earnings at $3.33 EPS and FY2025 earnings at $12.87 EPS.

MEDP has been the topic of several other research reports. Robert W. Baird raised their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $340.00 to $450.00 in a research report on Tuesday. Guggenheim lifted their price objective on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Price Performance

Shares of Medpace stock opened at $389.77 on Thursday. The firm has a 50 day simple moving average of $397.75 and a 200 day simple moving average of $324.12. Medpace has a fifty-two week low of $189.30 and a fifty-two week high of $421.00. The firm has a market cap of $12.08 billion, a P/E ratio of 39.73, a P/E/G ratio of 2.04 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same quarter in the prior year, the firm earned $2.27 EPS. The company’s revenue was up 17.7% on a year-over-year basis.

Insiders Place Their Bets

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Medpace news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the sale, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 189,340 shares of company stock worth $76,651,647. Insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently bought and sold shares of MEDP. Wellington Management Group LLP lifted its stake in Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after acquiring an additional 319,210 shares in the last quarter. TD Asset Management Inc increased its position in shares of Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after purchasing an additional 308,816 shares during the last quarter. Invesco Ltd. increased its position in shares of Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares during the last quarter. Norges Bank acquired a new position in shares of Medpace during the 4th quarter worth approximately $59,163,000. Finally, Epoch Investment Partners Inc. increased its position in shares of Medpace by 82.3% during the 4th quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock worth $108,040,000 after purchasing an additional 159,144 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.